Kurinami N, et al. - Researchers studied dapagliflozin-induced changes in liver fat accumulation in patients with inadequately controlled type 2 diabetes mellitus (T2DM). For this investigation, inadequately controlled T2DM was defined as hemoglobin A1c (HbA1c) <7.0%. Using abdominal computed tomography (CT), changes in liver fat accumulation were evaluated by the liver-to-spleen (L/S) attenuation ratio. Fifty-five Japanese T2DM patients were enrolled in this analysis. It was noted that additional dapagliflozin-treatment significantly decreased the liver fat accumulation associated with a reduction in abdominal subcutaneous fat area in patients with inadequately controlled T2DM.